Utilising Gamma-Delta T Cells to Mitigate Against Graft vs Host Disease
Time: 11:40 am
day: Day One
Details:
- Maximising the inherent benefits of γδT cells to avoid patient immune rejection
- Employing γδT cell receptors to target solid tumours without HLA
- Unlocking efficient large-scale manufacturing of a T cell subpopulation to generate allogeneic therapies
